Celldex
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Celldex and other ETFs, options, and stocks.About CLDX
Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases.
CLDX Key Statistics
Stock Snapshot
Celldex(CLDX) stock is priced at $24.37, giving the company a market capitalization of 1.62B. It carries a P/E multiple of -7.21.
As of 2025-11-11, Celldex(CLDX) stock has fluctuated between $22.10 and $24.77. The current price stands at $24.37, placing the stock +10.3% above today's low and -1.6% off the high.
The Celldex(CLDX)'s current trading volume is 1.51M, compared to an average daily volume of 1.07M.
In the last year, Celldex(CLDX) shares hit a 52-week high of $29.05 and a 52-week low of $14.40.
In the last year, Celldex(CLDX) shares hit a 52-week high of $29.05 and a 52-week low of $14.40.
CLDX News
Celldex Therapeutics (CLDX) is attracting interest following the release of new Phase 2 clinical trial data for barzolvolimab, presented at a major allergy and...
Celldex, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on t...
LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Celldex today and set a price target of $61.00. Meet Your ETF AI Analyst Discover how TipRanks' E...
Analyst ratings
81%
of 16 ratingsMore CLDX News
Investors in Celldex Therapeutics, Inc. (Symbol: CLDX) saw new options become available today, for the December 2026 expiration. One of the key inputs that goes...
LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Celldex today and set a price target of $61.00. Meet Your ETF AI Analyst Discover how TipRanks' E...